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 Prostate cancer micrometastasis allows cancer cells to vacate their original tumor 
sites and migrate to distant parts of the body via the bloodstream, lymphatic system, or by 
direct extension.  Cells synthesize and secrete matrix metalloproteinases (MMPs) that 
degrade proteins of the surrounding extracellular matrix (ECM); thus allowing them to 
escape into the lymphatic or circulatory systems to invade other tissues.  Transforming 
growth factor β (TGF-β) induces the migration and invasion of cancer cells and the 
expression of matrix metalloproteinases (MMPs), specifically MMP-2, and -9 in several 
malignancies.  In this study, we examined the role of MMP-7, a known activator of 
MMP-2 and MMP-9, in TGF-β signaling in cell proliferation, migration, and invasion in 
prostate cancer cells.  Basal expression levels of MMP7 mRNA, protein, and secreted 
protein were determined using RT-PCR, western blot analysis, and ELISA, respectively. 
Our data show that MMP7 mRNA and proteins were differentially expressed in several 
ii 
 
cell line models representing different stages of prostate cancer. TGF-β1 induces MMP-7 
gene expression and protein levels 24 and 48 hours after treatment in PC3 cells. Our data 
also show that TGF-β induces cell migration and invasion in PC3 and E006AA cells; 
however, the selective knockdown of MMP7 expression using siRNA resulted in a 
significant decrease in control and TGFβ-induced cell migration and invasion in both 
PC3 and E006AA cells. MMP-7 knockdown also caused significant reduction in cell 
proliferation in PC3 cells.  Our data suggest that MMP7 is essential for cell migration and 
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1.1  Background and Significance 
 
 1.1.1  Normal Prostate 
The prostate gland is a part of the male reproductive system responsible for the 
production and storage of seminal fluid.  In adult men, a normal prostate is nearly 3 
centimeters long and weighs approximately 20 grams.1  The prostate is positioned below 
the urinary bladder and directly in front of the rectum.  The prostate surrounds part of the 
urethra, the tube that carries urine from the bladder during urination and semen during 
ejaculation (Figure 1).2  
Figure 1. The prostate gland and prostate cancer.  
 





      The adult prostate is organized into three zones, a central zone, a transition zone, 
and a peripheral zone.2,3  The paired central zone is posterior to the stromal region in 
which approximately 20-25% of prostate cancers cases arise in this area of the gland.4,5  
Positioned interiorly to the central zone is the transition zone, which is located on either 
side of the urethra, and represents the smallest zone in the normal prostate.4,6,7  Prostate 
cancers arising from the transitional zone are larger at the time of diagnosis due to their 
central location, and the decreased likelihood of detection on digital rectal exam (DRE) 
or extended prostate needle biopsy schemes.4,5,7  Despite their greater total cancer volume 
at diagnosis, transition zone cancers are associated with lower Gleason scores at the time 
of prostate biopsy and prostatectomy.4,7,8 
The peripheral zone is the largest region of the normal adult prostate, and contains 
the majority of prostatic glandular tissue.  This zone is located on the posterior side of the 
prostate at the back of the gland closest to the rectal wall; and it is in this zone, that a 
doctor performs a DRE.  This peripheral zone is extremely important because 
approximately 70% - 80% of prostate cancers originate in this peripheral zone (Figure 
2).7-9  The significance of this architectural anatomy is based upon the relationship of 
these zones to prostatic disease. Benign prostatic hyperplasia (BPH), a nonmalignant 
overgrowth that is fairly common among aging men, occurs mainly in the transition zone, 
whereas prostate carcinoma arises primarily in the peripheral zone.3,10  Because of the 
prostate’s location, those affected may experience changes in urinary or sexual function, 






Figure 2. Anatomy of the prostate gland.   
 
Source: Figure adopted form the SIU School of Medicine Department of Surgery and Urology. 
 
 In Figure 2, the central zone is the area that surrounds the ejaculatory ducts. 
The transition zone surrounds the urethra as it enters the prostate gland, and is 
responsible for benign prostatic hyperplasia. The peripheral zone contains the 
majority of prostatic glandular tissue. The largest area of the peripheral zone is at the 
back of the gland, closest to the rectal wall.  
 
 1.1.2  Prostate Cancer 
Prostate cancer (PCa) is the third most common cause of male cancer-related 
deaths and the most common male non-cutaneous malignancy in Western population.12,13  
Globally, PCa is the second most common cause of cancer and the fifth leading cause of 
cancer-related death in men.14  More than 80% of men will develop prostate cancer by the 





age and other health problems as well as how aggressive and extensive his cancer is.  
Most men diagnosed with prostate cancer do not succumb to the disease.17   
The development of prostatic tumor in men is generally slow, taking up to 4 to 10 
years to develop a 0.4 inch-size tumor. 18,19  The initiation of PCa begins when the 
semen-secreting prostate gland cells mutate into tumor cells, proliferating at higher 
mitotic levels.  The prostate cells begin to proliferate leading to the formation of a tumor 
in the peripheral zone of the prostate gland.9,20  Over time these cancer cells continue to 
proliferate and begin to invade nearby organs, such as the seminal vesicles, rectum, 
bladder and urethra.21  In the early stages, malignant cells from the primary tumor detach 
from their original site(s) and migrate through blood and lymphatic vessels.22  Moreover, 
the lymph nodes adjacent to the primary tumor are often the first site of metastases. 23,24  
As this cancer progresses, cancer cells eventually spread to more distal organs, including 
bones, liver, and lung 21 and the patient finally succumbs to this disease. Unfortunately, 
most deaths from cancer occur as a result of metastasis.25 
 
 1.1.3  Risk Factors 
Comprehensive understandings of the exact cause(s) of prostate cancer have not 
yet been clearly established.26,27  However, researchers have found several factors that 
may increase the risk of a man developing prostate cancer.  Some of these factors 
include: age, race/ethnicity, family history, and obesity.28,29  Prostate cancer diagnoses 
are fairly uncommon in men under the age of 45, and become more prevalent as a man 
advances in age.29  The median age for prostate cancer diagnosis in men is 70 years of 





Several research studies have demonstrated that prostate cancer disproportionately 
affects African Americans and Caribbean men, which suggest that aspects associated 
with African ancestry, may be a factor in prostate cancer etiology.28,29  Additionally, 
African American men have the world's highest incidence of prostate cancer and a more 
than two fold higher mortality rate as compared to their white counterparts.27,29   In 
contrast, the incidence and mortality rates for Hispanic men are one third lower than for 
non-Hispanic white.27 
Approximately one in six American men diagnosed with prostate cancer will die 
from the disease.27  The world's highest mortality rates (30.3 to 47.9 per 100,000 person-
years) were seen in men of African descent in the Caribbean nations of Barbados, the 
Bahamas, and Trinidad and Tobago. 27 
A recent study, found that African Americans and Hispanics were generally 
younger, less educated, poorer, and less likely to have had a previous PSA (prostate 
specific antigen) test than non-Hispanic whites.27  Furthermore, non-Hispanic whites 
were less likely than African Americans or Hispanics to have urinary symptoms, to be 
unemployed, on public insurance (Medicare or Medicaid), or uninsured.27  Among all 
study subjects, African Americans had the most comorbidity and the highest PSA 
levels.28  Overall, African Americans (16.8%) and Hispanics (12.9%) had a higher 
proportion than non-Hispanic whites (10.5%) of poorly differentiated cancers which 
coincide with Gleason scores of 8–10.28,29   
Genetic background has been implicated in the development of prostate cancer 





have a first-degree relative (father or brother) with prostate cancer have twice the risk of 
developing prostate cancer compared to those who do not have a first degree relative.12 
Additionally, those with two first-degree relatives affected have a fivefold greater risk 
compared to those with no family history.12  Moreover, African-American men have 
twice the risk of non-Hispanic whites for presenting with advanced-stage prostate 
cancer.28,29  
Several genes have been implicated in the development of prostate cancer.30  
Mutations within BRCA1 and BRCA2, (Breast Cancer Genes 1 & 2), genes have been 
shown to be important risk factors in the development of ovarian cancer and breast cancer 
in women.31,32  These genes have also been implicated in the development of prostate 
cancer.33  Other genes implicated in the development of prostate cancer are hereditary 
prostate cancer gene 1 (HPC1), the androgen receptor, and the vitamin D receptor.27  
Two genome-wide association studies linking single nucleotide polymorphisms 
(SNPs) to prostate cancer were published in 2008.14,15  These studies identified several 
SNPs which have substantial effects on the risk of developing prostate cancer.  For 
instance, individuals with the TT allelic pair at SNP rs10993994 were reported to have an 
approximately 1.6 times greater risk of developing prostate cancer than those with the CC 
allele pair.34,35  This SNP explains part of the increased prostate cancer risk of African- 
American men as compared to American men of European descent, since the T allele is 
much more prevalent in African-American men.35,36  This SNP is located in the promoter 
region of the microseminoprotein-Beta (MSMB) gene, thus affecting the amount of 





is not known whether the risk factors explaining the observed patterns are related to the 
environment, lifestyle, or genetics, it is likely that a complex interplay of these factors is 
associated with prostate cancer etiology.28,29 
 
 1.1.4  Prostate Cancer Diagnosis 
Prostate cancer is a relatively asymptomatic disease at the early onset and does 
not show symptoms until the later stages of the disease.  Consequently, men must be 
screened to detect evidence of cancer.  As a result, many medical organizations and 
health care professionals have strongly advocated that men begin screening in their 50s, 
or sooner for those who have been determined to be at greater risk for developing PCa.    
The primary diagnostic tools in the diagnoses of PCa are the detection of serum 
level concentration of PSA and the DRE. The majority of prostate cancers diagnosed in 
the United States are diagnosed by PSA testing, although many experts have concluded 
that the efficacy of PSA screening is insufficient.19,37,38  Nevertheless, it has been shown 
that PSA screening reduces PCa-related mortality by 21% - 44%.39,40  On the other hand, 
nearly 18% of all patients’ PCa is detected by a suspect DRE alone regardless of the 
detected PSA levels.41  DRE remains an important staging component for more advanced 
disease.42   However, if one or more of these screening examinations are abnormal, 
further investigation should ensue via transrectal ultrasound (TRUS) guided biopsy.   
Upon a positive diagnosis of cancer by a trained pathologist, the sample obtained 
from the biopsy is then staged by the Gleason grading system. The Gleason system was 
developed by Dr. Donald F Gleason and members of the Veterans Administration 





widely utilized grading scheme in the United States and worldwide.43-46  The Gleason 
grading system is based exclusively on the histological microscopic arrangement of 
cancer cells in Haemotoxylin and Eosin (H&E) stained prostatic tissue sections 43,46,47 
obtained from patient biopsies.  The system initially analyzed nine different growth 
patterns and consolidated them into five basic grade patterns which are used to generate a 



























Figure 3. The Gleason grading system.  
 
Source: Figure adopted from Gleason, D. F. The Veteran's Administration Cooperative Urologic Research 
Group: Histologic Grading and Clinical Staging of Prostatic Carcinoma. Tannenbaum: Philadelphia, 





The Gleason score is calculated by adding the primary grade pattern and the 
secondary grade pattern. The primary pattern is the one that is predominant in area, by 
simple visual inspection, and the secondary pattern is the second most common pattern.  
However, if only one grade is in the tissue sample, that grade is multiplied by two to give 
the score.45-48  The Gleason score assigned by the pathologist at the time of diagnosis 
significantly influences the treatment options offered to the patient, because carcinomas 
designated with higher Gleason scores indicate more aggressive cancers and higher risks 






Figure 4. Gleason scores for prostate cancer diagnosis.  
Source: Figure obtained from www.cancer.gov 
Once prostate cancer has been confirmed by a biopsy, it is imperative to learn the 
stage (location) and grade (aggressiveness) of the tumor, since a patient’s treatment 
options are generally tailored to the patient’s age and tumor stage.  Although there has 
been some controversy surrounding the issue of tumor staging, the Gleason system 












Figure 5. The stages of prostate cancer.   
Source: Figure obtained from www.cancer.gov.  
  
 1.1.5  Treatment Options 
Following subsequent diagnosis of PCa, a patient’s treatment options vary and are 
based upon the risk factors of their prognosis as being either: low risk, intermediate risk, 
or high risk.49-51  A low risk diagnosis comprises a PSA concentration less than or equal 
to 10 ng/mL, a Gleason score which less than or equal to 6, and cancer localized within 
the prostate gland being staged 1-2a.  Patients in this category are often candidates for an 
active surveillance program, previously referred to as “watchful waiting/active 
surveillance therapy.”44  These patients also have the option(s) to undergo radical 
prostatectomy, external beam radiotherapy, brachytherapy with permanent implants or 
high dose rate brachytherapy with temporary implants.44,52   
An intermediate risk diagnosis entails a patient’s PSA levels that are between 10-
20 ng/mL, have a Gleason score of 7, and possess a clinical stage of 2b.  Patients in this 
category are likely to benefit from radical prostatectomy, radical surgery, external beam 





with temporary implants, or active surveillance) and do well with these treatment. 51,52  
Patients deemed as high risk patients and classified by PSA levels greater than 20 ng/mL,  
Gleason scores of 8-10, and have a cancer clinically staged as 2c-3 normally undergo 
radical prostatectomy or external beam radiotherapy plus (neo)adjuvant treatments.51 
  The relative 5-year survival rate for PCa patients with localized disease is nearly 
100%.53,54  Moreover, the 10-year and 15-year relative survival rates are 98% and 95%, 
respectively.54  However, when discussing treatment options for patients diagnosed with 
PCa, one must also consider patients diagnosed with advanced and aggressive forms of 
the disease, whose 5-yr survival rates swiftly decline to 28%.53,54  For these men, 
treatment options include androgen deprivation therapy (ADT), chemotherapy, bone-
directed therapy, radiation, or a combination of these treatments.55  Nevertheless, there is 
always the fear of recurrence of the disease, the increased probability of death due to 
cancer, and the complications of treatment. 
 
 1.1.6  Growth Factors that Promote Prostate Cancer 
      Growth factors (GFs) are naturally occurring regulatory molecules, which bind to 
receptors on the cell surface. They stimulate cell and tissue function through 
influencing cell differentiation and by changing their biochemical activity and cellular 
growth, and regulating their rate of proliferation.56  Structurally GFs are peptide-like 
hormones; however they are not limited to defined tissues.56  They act on target tissues in 
both diffusible (endocrine, autocrine and paracrine) and nondiffusible (juxtacrine or 
metacrine) manners and regulate a variety of cellular events which include cell migration, 





action, and many utilize the tyrosine kinase receptor pathway amongst other common 
signal transduction pathways such as MAP kinase signaling, JAK/STAT signaling, and 
PI3K/AKT1/MTOR signaling pathways.  Therefore, any mutation(s) affecting signal 
transduction may affect several growth factor pathways simultaneously.58  
      GFs are present in a variety of tissues, both adult and embryonic, and are thought 
to be released by many, if not all, cells in culture.59  Membrane receptors for growth 
factors are also highly ubiquitous with most cells having receptors for more than one 
growth factor.60  Numerous studies have demonstrated that multiple growth factors are 
required for maximum stimulation of specific cell types; and exposure of a cell to one 
growth factor can lower the threshold for mitogenicity of a second growth factor.61-63   
      Research has also shown that GFs operate at different points of the cell cycle, and 
these GF are essential in several phases of tumor progression.58,63  Moreover, there is 
evidence to support a major role in normal and cancerous growth of the prostate from a 
variety of GF families which include the fibroblast growth factor (FGF) family, the 
insulin-like growth factor (IGF) family, epidermal growth factor family (EGF), and 
transforming growth factor α (TGF-α), all of which are predominantly stimulators of 
proliferation; retinoic acid, which causes differentiation and invasiveness; the TGF-β 
family, which are predominantly inhibitors of prostatic growth in normal cells and a 
tumor promoter in malignant cells; and the vascular endothelial growth factor (VEGF) 
family, which predominantly stimulate angiogenesis.64  According to numerous studies, 






The human FGF gene family of growth factors consists of at least 23 different 
genes encoding related polypeptides.64  FGFs are expressed in almost all tissues and play 
important roles in a variety of normal and pathological processes, including development, 
wound healing and neoplastic transformation.  The FGFs are mitogenic for many cell 
types, both epithelial and mesenchymal.64  Moreover, FGFs have been shown to increase 
the motility and invasiveness of a variety of cell types and can even inhibit cell death in 
the appropriate context.  Thus, FGFs have a broad range of biological activities that can 
play an important role in prostate tumorigenesis.64 
FGFs interact with a family of four distinct, high-affinity tyrosine kinase 
receptors, designated FGFR-1 to -4.  Binding of FGFs to the extracellular domains of 
FGF receptors results in receptor dimerization and transphosphorylation of tyrosine 
residues in the intracellular domain that is required for FGF receptor kinase activation. 
Ultimately, activation of FGF receptors leads to signal transduction through multiple 
pathways including phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein 
kinases (MAPK), and signal transducers and activators of transcription (STATs).67-70  
These effectors in turn disseminate the receptor tyrosine kinase signals by activating 
many target proteins, including transcription factors in the nucleus.64,70  
The human IGF gene family consists of: two ligands (IGF-I and IGF-II), two 
receptors (IGF-IR and IGF-IIR), six high-affinity binding proteins (IGFBPs 1–6), a large 
group of IGFBP proteases and a new group of proteins, low-affinity IGFBP-related 





among themselves and with other GF families and their signaling pathways, including 
MAPK, ERK, and PI3K.71 
The EGFR family is comprised of four members; c-erbB-1 (EGFR), c-erbB-2 
(HER2/neu), c-erbB-3 (HER3) and c-erbB-4 (HER4).72,73  This family of GFs signals 
primarily via Receptor tyrosine kinases (RTKs) and is a key factor in epithelial 
malignancies.  The activity of this GF enhance tumor growth, invasion, and metastasis 
not only tumor cells, but also tumor-associated endothelial cells.  To date, six mammalian 
ligands that bind to EGFR have been characterized, including: epidermal growth factor 
(EGF), transforming growth factor-α (TGFα), amphiregulin, heparin-binding EGF-like 
growth factor, betacellulin, and epiregulin.74,75  Once activated by ligand binding, the 
receptor subsequently stimulates multiple signal pathways which include: Ras/MAPK, 
PI3K/AKT, NFκB, and others.76-78 
EGF and TGF-α are structurally similar and hence are similar in their ability to 
bind and regulate the EGFR.65  Their biological activities over-lap and include roles in 
embryogenesis, cell differentiation, and angiogenesis.79  The normal prostate contains 
large amounts of EGF produced by the epithelial cells, and Immunohistochemical studies 
have located TGF-α production principally in the stromal cells in normal prostatic 
tissue.80  Moreover, increased expression of EGF/TGF-α has been linked to prostate 
cancer development.81 
Three proteins of the TGF-β superfamily, TGF-β1, TGF-β2, and TGF-β3, are 
expressed during prostate development and in the adult prostate in both normal and 





the expression of TGF-β2 and TGF-β3 are more tissue-restricted.83-85  However, all three 
isoforms share a multiplicity of biological effects.83  Although TGFβR-I and TGFβR-II 
are transmembrane serine-threonine kinases,86 they can trigger decreases in the 
expression of members of the Src family of tyrosine kinases86 affecting protein tyrosine 
kinase signaling and hence growth regulation.  Additionally, TGF- β can oppose the 
mitogenic effects of the stimulatory growth factors of IGF-I, EGF, TGF-α, bFGF, and 
KGF in normal tissues.87,88 
The VEGF family is a family of glycosylated protein that exists in at least five 
isoforms.  Members of the VEGF family include VEGF/VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F, and Placental Growth Factor (PlGF).89  VEGF is one of the 
most important promoters of angiogenesis and vascular permeability, especially during 
embryogenesis, skeleton growth and reproductive functions.90  This family of GFs signal 
primarily through tyrosine kinases VEGFR1 and VEGFR2 and stimulate cell survival, 
proliferation, migration, and/or adhesion.90 The expression of VEGF is regulated by 
hypoxia, and hypoxic induction leads to up-regulation of VEGF and a then a subsequent 
increase in blood vessels formation.90  VEGF appears to play a role in the growth of 
prostate cancer, contributing to angiogenesis thus permitting tumor progression.91  The 
human prostate relies on a range of growth factors for its normal growth and 
development.  Many of these pathways have been shown to be upregulated in prostate 
cancer and there is strong evidence linking each of these pathways to prostate cancer 







 1.1.7  Rationale for Focusing on MMP-7  
Matrilysin (MMP-7) is a member of the MMP gene family that has an essential 
role in tumor invasion.  Following activation, MMP-7 displays broad proteolytic activity 
against a variety of ECM substrates which include: proteoglycans, elastin, laminin, 
fibronectin, and casein.92-94  MMP-7 has been shown to be overexpressed in malignant 
tumor cells including, prostate, gastric, head, and neck, lung, hepatocellular, and 
colorectal carcinomas.93  MMP-7 mRNA has also been shown to increase as colorectal 
cancer progresses.92  
Compared to other MMPs, MMP-7 is unique due to the lack of a C-terminal 
domain, which gives it a low molecular mass of 28 kDa.95,96  This unique structure and 
pattern of localization (being secreted by malignant cancer cells, versus being secreted 
from stromal cells such as MMP-2,-9 and -13) suggest that this enzyme may function in a 
manner distinct from other MMPs, and may contribute directly to the invasive potential 
of colorectal carcinomas and other epithelial cancers.92  Furthermore, the expression of 
MMP-7 has been significantly correlated with the presence of nodal or distant 
metastases.97  In addition to invasion, migration, and metastasis, active MMP-7 has also 
been shown to cleave (activate) the propeptides of proMMP2 and proMMP9 (two of the 
most studied MMPs) to facilitate tumor invasion.97,98  However, relatively little is known 
about the function of MMP-7, in prostate cancer. 
Therefore, the aim of this study was to examine the relationship between TGF-β 
and matrix metalloproteinase-7 (MMP-7) expression in prostate cancer cells and to 





cancer cells.  This study is the first to investigate the role of TGF-β1 in the induction of 
matrix metalloprotease‑7 (MMP‑7) and the effects on cell proliferation, migration, and 
invasion in PC3 and E006AA cell lines. 
 
1.2  Research Questions 
 In normal epithelial cells, TGF-β has been shown to induce growth inhibition of 
most cell types by causing cell cycle arrest in the G1 phase.99  This process is initiated 
when TGF-β induces the expression of the cyclin-dependent kinase (CDk) 4/6 inhibitor 
p15Ink4B (p15) 100 and represses the expression of c-Myc.101  In certain cell types, TGF-
β also upregulates p21,102 a CDK2 inhibitor, and down-regulates cdc25A, a phosphatase 
that activates CDK2.103  Induction of CDK inhibitors appears to represent key events in 
TGF-β induced growth arrest.  However, as normal cells transform into cancer cells, they 
develop a resistance to the growth inhibitory effects of TGF-β,104-106 and TGF-β acts as a 
tumor promoter within these cells and exerts positive effects on migration, invasion, 
angiogenesis, and metastasis.104,106,107   
Our laboratory has demonstrated the increased migratory and invasive behaviors 
induced by TGF-β.108  Moreover, previous studies have shown that MMPs are essential to 
the migratory and invasive behaviors of advanced carcinoma cells.109-111  Yet no study 
has determined the correlation of the effects TGF-β on the regulation of MMP-7 in 
prostate cancer cells.  Therefore, the aim of this study was to answer the following 
research questions:  
RQ1: What are the effects of TGF-β on the regulation of matrix 





RQ2: What are the function(s) of MMP-7 in TGF-β mediated cell migration, 
invasion, and proliferation? 
 
1.3  Hypotheses 
The hypotheses of this research are as follows:  
HO1: TGF-β can regulate both the expression and protein levels of MMP-7 in 
prostate cancer cells.   
HO2: MMP-7 plays a pivotal role in the processes of TGF-β mediated cell 
proliferation, migration, and invasion in prostate cancer cells.   
 
1.4  Specific Aims    
To test the hypotheses and answer pertinent research questions associated with 
this current study, the following aims were adopted: 
 1.4.1  Specific Aim 1  
1A.  To determine the basal expression of MMP-7 mRNA, relative protein levels, 
and secreted protein levels of normal prostate epithelial cells and prostate 
cancer cell lines.  
1B.  To determine the effects of TGF-β1 on MMP-7 expression and protein levels 
in prostate cancer cells.   
 Rationale: In the initial stages of invasion and metastasis of neighboring tissues 
metastatic cancer, cell migration and invasion have been shown to be contingent 
upon the degradation of the extracellular matrix (ECM).  This process leads to the 
subsequent escape of cancer cells from their confined positions within the solid 





activation of various MMPs.  Moreover, previous studies have shown TGF-β to 
regulate the expression of various MMPs.  Moreover, MMPs produced by either 
cancer cells or residents’ stromal cells activate latent TGF-β in the extracellular 
matrix, together facilitating the enhancement of both tumor development and 
progression [35]. Thus, MMPs have been chosen as promising targets for cancer 
therapy on the basis of their aberrant up-regulation in malignant tumors and their 
ability to promote cancer metastasis in response to TGF-β signaling [38].  
Therefore, the researcher investigated the potential involvement of the TGF-β 
pathway and its effects on the regulation of MMP-7 in TGF-β mediated cell 
migration, invasion, and proliferation in PC3 and E006AA cell lines.      
 
 Experimental Design: The basal expression levels of MMP-7 mRNA and protein 
was determined using prostate and prostate cancer epithelial cells seeded in 10 cm 
dishes and allowed to grow for 48 hours.  Immediately after this culturing period, 
the cell culture media was collected to analyze the amount of protein contained in 
the conditioned culture media.  After removing the conditioned culture media 
from the cells, the cells were lysed and both RNA and protein was extracted and 
analyzed for MMP-7 mRNA and protein expression using reverse transcription 
polymer chain reaction (RT-PCR) and Western Blot respectively. In order to 
determine the effects of TGF-β1 on MMP-7 mRNA expression and relative 
protein levels, PC3 prostate cancer cells lines were seeded to ~80% confluency in 
6-well plates and treated with 5ng/ml of exogenous TGF-β1 at varying time 





 1.4.2  Specific Aim 2  
 To determine the role of MMP-7 in TGF-β mediated cell migration, invasion, and 
proliferation of prostate cancer cells.  
 
 Rationale:  The process of metastasis includes the multifaceted process of 
proliferation, migration, and invasion.  Moreover, numerous studies have shown 
that MMPs are required for the processes of cell migration and invasion due to 
their role in degrading the extracellular matrix and basement membrane, thus 
facilitating metastasis and angiogenesis.  Therefore, in efforts to develop more 
effective therapeutic strategies we will determine the function of MMP-7 in the 
multifaceted processes of TGF-β mediated cancer cell migration, invasion, and 
proliferation in prostate cancer cell lines.  
 
 Experimental Design: PC3 and E006AA cells lines were be seeded in 6-well 
plates and grown to ~80 % confluency; the cells were transiently transfected to 
knockdown the MMP-7 protein using siRNA specific for MMP-7. The transfected 














  LITERATURE REVIEW 
 
  
2.1  Transforming Growth Factor Beta (TGF-β) 
The transforming growth factor beta (TGF-β) superfamily consists of more than 
30 related members in mammals, including 3 TGF-βs, 4 activins, inhibins, and over 20 
bone morphogenetic proteins (BMPs).112-114  TGF-β and its receptors are widely 
expressed in all tissues of the body and its signal transduction pathways have been 
implicated in the pathogenesis of many diseases, ranging from autoimmune disorders and 
infectious diseases to fibrosis and cancer.115,116  TGF-β modulates cell proliferation, 
differentiation, apoptosis, adhesion, and migration, in various cell types and favors the 
production of extracellular matrix proteins, and is the dynamic inducer of ECM 
generation known thus far.113,117,118  TGF-β also plays an important role in the regulation 
of extracellular matrix synthesis, degradation and remodeling by stimulating the synthesis 
of collagens,119 fibronectin,120 proteoglycans, tenascins, thrombopondin, plasminogen 
activator inhibitor-1 (PAI-1),121 and tissue inhibitor of metalloprotease-1 (TIMP-1).122  
Most cell types, including immature hematopoietic cells, activated T and B cells, 
macrophages, neutrophils, and dendritic cells  produce TGF-β,123,124 and all human cell 





There are three known isoforms of TGF-β, and each isoform is encoded by a 
unique gene on different chromosomes.  TGF-β1 is located on chromosome 19 (19q13.1), 
TGF-β2 on chromosome 1 (1q41), and TGF-β3 on chromosome 14 (14q24).127  These 
growth factors are secreted by most cell types and are expressed in mammalian 
tissues.128,129  However, they display distinctive and at times overlapping, spatial and 
temporal expression patterns.130  These isoforms contain highly conserved regions, but 
diverge in several amino acid regions.  Yet, all three isoforms function via the same 
receptor signaling pathways.116,131  TGF-β1 and TGF-β2 share 71% sequence 
homology,131 whereas TGF-β3 shares an 80% sequence homology with both TGF-β1 and 

















TGF-β1 is the most abundant and ubiquitously expressed isoform, and its mRNA 
and/or protein have been localized in cartilage, endochondral, and bone and skin, which 
suggest their role in the growth and differentiation of these tissues.116,133  TGF-β2 was 
first described in human glioblastoma cells.134  Physiologically, TGF-β2 is expressed by 
neurons and astroglial cells in the embryonic nervous system.135  It is also important in 
tumor growth enhancing cell proliferation in an autocrine way and/or reducing immune-
surveillance of tumor development.136,137  The levels of TGF-β3 have been significantly 
detected in cartilage, bone, brain and lung, and mesenchymal cells. 130,138   
 
2.2  TGF-β Signal Transduction  
 Members of the TGF-β family are always synthesized as an inactive complex that 
must be activated to enable binding to its receptor and subsequent function.118,139  
Following activation, most TGF-β superfamily members convey signals via heteromeric 
complexes of transmembrane serine/threonine kinases, TGF-β type I (TβRI) and TGF-β 
type II (TβRII) receptors.140  The TGF-β signaling pathway is activated by ligand binding 
to the extracellular domain of the type II receptors.  This binding induces a 
conformational change resulting in subsequent phosphorylation and activation of type I 
receptors.141  The activated type I receptor then phosphorylates the appropriate Smad 







































Figure 7. TGF-β and SMAD activation pathway with co-activatiors, co-
repressors, and transcription factors.  
 
Source:  Poniatowski, Ł. A.; Wojdasiewicz, P.; Gasik, R.; Szukiewicz, D. Transforming Growth Factor 
Beta Family: Insight into the Role of Growth Factors in Regulation of Fracture Healing Biology and 
Potential Clinical Applications. Mediators of Inflammation. 2015:137823. 
 
 
The Types I and II receptors have an N-glycosylated extracellular domain which 
is rich in cysteine residues, one transmembrane domain, and an intracellular 
serine/threonine kinase domain.  The type II receptor kinase is a constitutively active 
kinase, whereas the type I receptor kinase needs to be activated by the type II receptor 





receptor phosphorylates the type I receptor in a region rich in glycine and serine/ 
threonine residues (termed the GS domain).113,116  This phosphorylation changes the 
conformation of the type I receptor, thereby activating its kinase.  The activated type I 
receptor then propagates the signal by phosphorylating specific intracellular proteins.  
Thus, the type I receptor acts downstream of the type II receptor and consistent with this 
notion, has been shown to determine signaling specificity.113,114,142 
The Smad family can be divided into three distinct subfamilies: receptor-regulated 
Smads (R-Smads: 1,2,3,5,8 and 9), common-partner Smads (Co-Smads: Smad4) and 
inhibitory Smads (I-Smads: Smad 6 and 7).114,143  Activation of the various R-Smads: is 
predicated upon which member of the TGF-β superfamily is binding to the receptor 
initiating signal transduction.  BMPs activate R-Smads Smad1, Smad5, and Smad8, 
whereas TGF-β or activin activate R-Smads: Smad2 and Smad3.112,113,134  Following 
phosphorylation, the activated R-Smads recruit Co-Smads (Smad4) which forms a 
heteromeric complex and translocates into the nucleus.144   
Nuclear Smad complexes then bind to DNA directly or indirectly through other 
DNA-binding proteins and additional cofactors in order to achieve high binding affinity 
and selectivity to regulate the transcription of specific target genes.134,144,145  Smad4 lacks 
the C-terminal motif found in all R-Smads and is not phosphorylated following activation 
of TGF-β receptors.146,147  It functions as a convergent node in the Smad pathways 
downstream of TGF-β superfamily receptors, complexing not only with TGF-β/activin-
activated Smad2 and Smad3 but also with BMP-activated Smad1, Smad5, and 





Conversely, ligand-activated Smad2 and Smad3 translocate to the nucleus in a Smad4-
independent fashion.146,147  This implies, by default, that the principal function of Smad4 
is to regulate transcription rather than to transmit the signal from the cytoplasm to the 
nucleus.  
 
2.3  TGF-β in Cancer 
As previously stated, TGF-β has a biphasic role in tumorigenesis and cancer cells 
use TGF-β to enhance their characteristic properties and features.148  In the later stages of 
cancer, malignant cells can evade the suppressive effects of TGF-β either through 
inactivation of core components of the pathway, such as TGF-β receptors, or by 
downstream alterations that disable just the tumor-suppressive arm of this pathway.125  
By doing so, cancer cells can hijack the remaining TGF-β regulatory functions to their 
advantage, thus acquiring invasive capabilities, producing autocrine mitogens, and/or 
releasing prometastatic cytokines.125  
It is worth noting, that as cancer advances, so too does the overexpression of 
TGF-β in many late-staged and even metastatic human tumors.149-151  During this process, 
epithelial polarity is gradually lost, organ structure is disrupted and epithelial cells 
dedifferentiate.  Progression to metastatic carcinomas requires additional changes, such 
as proteolytic degradation of the basement membrane, conversion from a sessile to a 
migratory phenotype, survival in the blood stream and formation of metastases at distant 
sites.152  Moreover, TGF-β has been shown to play a role in these caveats of cancer 





Recent experimental studies demonstrate the ability of TGF-β to fully induce 
polarized, non-invasive epithelial cells so that they acquire a mesenchymal, spindle cell 
phenotype (which is EMT).153  The mesenchymal cells obtained after EMT in vitro or 
cultivated from tumors were invasive in several in vitro assays.  They also displayed 
autocrine production of TGFβ, which is required to maintain the mesenchymal, spindle-
like, invasive cell phenotype.  Additionally, neutralizing antibodies to TGFβ caused 
reversion to a polarized, epithelial phenotype.153  Interestingly, TGF-β production by the 
tumor cells and the acceleration of EMT by exogenous TGFβ was demonstrated in 
vivo.153 
Experimental studies show that blocking TGF-β1 signaling in the primary tumor 
reduces metastasis.  In patients with hereditary non-polyposis colorectal cancer (HNCC), 
TβRII is inactivated and the cells no longer respond to TGF-β signaling and display 
reduced metastasis and longer survival rates than patients with sporadic colon cancers.154  
Equally expression of a dominant negative truncated TβRII in highly metastatic colon 
carcinoma155 and breast carcinoma cell line156 blocked metastasis.  These findings are 
evidence of the essential role that TGF-β plays in the multifaceted process of cancer 
metastasis. 
 It has been established that TGF-β signals via the canonical Smad signaling 
cascade.  However, evidence suggests that the non-canonical signaling pathways are 
primarily involved in the induction of EMT by TGFβ.  Signaling through integrin β1,157 






A,157,161 Jagged/Notch, 162 nuclear factor κβ (NF-κβ) 163 have all been shown to be 























Figure 8: TGF-β canonical and non-canonical signaling pathways.  
 
Source: Figure adopted from Costanza, B.; Umelo, I. A.; Bellier, J.; Castronovo, V., et al.  Stromal 
Modulators of TGF-β in Cancer. J. Clin. Med. 2017; 6 (1), 7. Canonical and non-canonical TGF-β 
signaling pathways. (A) The canonical signaling pathway, biologically active TGF-β ligand binds to 
TGFβRII, which activates TGFβRI. TGFβRI-regulated SMAD2/3 proteins are phosphorylated at C-
terminal serine residues and form complexes with SMAD4 (co-SMAD), initiating transcriptional regulation 
of target genes. (B) The non-canonical signaling pathways, the TGF-β receptor complex transmits its signal 
through other factors, such as the mitogen-activated protein kinases (MAPKs), phosphatidylinositide 3-
kinase (PI3K), TNF receptor-associated factor 4/6 (TRAF4/6) and Rho family of small GTPases.  
 
The initiation of multiple signaling pathways downstream of the activated 
receptor complex reveal the true pleotropic effects of TGF-β.164  Emerging evidence 
revealed that both TGF-β canonical and non-canonical signaling cascades can 
simultaneously occur through crosstalk of core pathway components and combined 
utilization of SMAD/non-SMAD transcription factors.164  Although it is widely believed 





Smad-dependent pathway has also been implicated in select cases.  TGFβ signaling 
through TβRI and TβRII has also been implicated for TGFβ-mediated EMT and Smad 
overexpression has been shown to cause synergistic induction of EMT when combined 
with activated TGFβ receptors.155 
 
2.4  Matrix Metalloproteinases (MMPs) 
MMPs are a family of over 25 genetically distinct but structurally related zinc-
dependent matrix-degrading enzymes110 who share similar structures, and possess the 
ability to degrade virtually all components of the ECM.165-168  MMPs are initially 
synthesized in an enzymatically inactive state due to the interaction of a cysteine residue 
of the pro-domain with the zinc ion of the catalytic site.169   Based on their domain 
structure and substrate preferences, MMPs are traditionally grouped into the following 
categories (1) collagenases, including MMP-1, -8, -13; (2) stromolysins, MMP-3 and 
MMP-10; (3) gelatinases, MMP-2 and MMP-9; (4) matrilysins, MMP-7 and MMP-26; 













































Figure 9. Classifications, structures, and domain of the Matrix 
Metalloproteinases.  
 
Sources: Figure adopted from Radisky, E. S.; Radisky, D.C. Matrix Metalloproteinase-Induced Epithelial-
Mesenchymal Transition in Breast Cancer. J Mammary Gland Biol Neoplasia. 2010;15(2), 201-212.  
Ting-Yen, C-M; Tsaoab, Chao-BinYehac; Shun-FaYang, Matrix Metalloproteinases in Pneumonia. Clinica 
Chimica Acta. 2014;43(10), 272-277. The various domain organizations of human MMPs are illustrated; S, 
signal peptide; Pro, propeptide; CAT, catalytic domain; F, fibronectin repeats; PEX, hemopexin domain; 
TM, transmembrane domain; GPI, glycophosphatidylinositol membrane anchor; C, cytoplasmic domain; 
CA, cysteine array; Ig, immunoglobulin-like domain. The flexible, variable length linker or hinge region is 
depicted as the curved black line connecting domains.  
  
Under normal physiological conditions, the proteolytic activities of MMPs 
influence plethora of cellular process like cell proliferation, migration, and adhesion, as 
well as many fundamental physiological events involving tissue remodeling such as 





involution.170,171  They also play an integral role in opposing the effects on angiogenesis; 
regulation of cell growth via cleavage of cell surface-bound growth factors and receptors; 
release of growth factors sequestered in the ECM (including Transforming Growth 
Factor-α (TGF-α);172 regulation of apoptosis via release of death or survival factors; 
alteration of cell motility by revealing cryptic matrix signals or cleavage of adhesion 
molecules; and effects on the immune system and host defense.173   Moreover, MMPs 
have also been shown to affect the bioavailability of TGF-β, by releasing it from an 
inactive complex.174  
The expression of many MMPs is precisely regulated at the level of transcription 
by a variety of growth factors, cytokines, and chemokines, though post-transcriptional 
pathways may contribute to this regulation in specific cases.175,176   This usually results in 
relatively low basal levels for these enzymes under normal physiological conditions.177  
The proteolytic activity of MMPs is mainly regulated by tissue inhibitors of MMPs 
(TIMPs).  Four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) have been described 
and they can inhibit all active MMPs, however, not with the same efficacy.178-180  A loss 
of activity control may result in diseases such as arthritis, cancer, atherosclerosis, 
aneurysms, nephritis, tissue ulcers, and fibrosis. 
 
2.5  Matrix Metalloproteinases in Cancer 
Tumor cells fulfill their metastatic potential after acquiring advantageous 
characteristics, which allow them to escape from the primary tumor site, migrate and 
invade surrounding tissues, enter the vasculature, circulate and reach secondary sites, 





cells require the assistance of a variety of proteolytic enzymes.  The MMPs, as their name 
implies, are associated with degradation of the extracellular membrane (ECM), including 
the basement membrane, which is a specialized matrix composed of type IV collagen, 
laminin, entactin, proteoglycans, and glycosaminoglycans.184   
In cancer, MMPs are believed to promote tumor progression by enhancing growth 
via angiogenesis, disrupting local tissue architecture to allow tumor growth, and 
degrading basement membrane barriers to facilitate metastatic spread.166  As a result, the 
expression and activity of MMPs in a variety of human cancers have been studied 
intensively, and their expression and activity have been found to be increased in virtually 
every type of human cancer.185 
These findings also correlate with advanced tumor stage, increased invasion, and 
metastasis, and shortened survival.186  Mounting evidence demonstrates that MMPs are 
involved in the earlier stages tumorigenesis (e.g., in malignant transformation, 
angiogenesis, and tumor growth both at the primary and metastatic sites).175,187,188  Thus, 
MMPs have been considered as potential diagnostic and prognostic biomarkers in many 
types and stages of cancer.189 
Cancer progression involves different stages including tumor growth, invasion, 
metastasis, and angiogenesis all of which can be modulated by MMPs.190,191  The 
expression of MMPs in the tumor microenvironment depends not only on the cancer 
cells, but also on the neighboring stromal cells. MMPs exert their proteolytic activity to 
degrade the physical barriers, thus facilitating angiogenesis, tumor cells invasion and 





signaling molecules, such as growth factors and cytokines, by MMPs making these 
factors more accessible to the cancer cells and the tumor microenvironment.  This occurs 
by liberating them from the ECM (IGF, bFGF and VEGF) or by shedding them from the 
cell surface (EGF, TGF-α, HB-EGF). Angiogenesis is also tightly modulated by the 
release of negative regulators of angiogenesis, such as angiostatin, tumstatin, endostatin, 
and endorepellin.  MMPs also modulate the cell–cell and cell–ECM interactions by 
processing E-cadherin and integrins, respectively, affecting both cell phenotype (EMT) 





























Figure 10: Pivotal roles of MMPs in the four hallmarks of cancer: migration, invasion, 
metastasis, and angiogenesis.  
 
Source: Figure adopted from Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of Matrix 






MMPs have been chosen as promising targets for cancer therapy on the basis of 
their aberrant up-regulation in malignant tumors and their ability to promote cancer 
metastasis.180,195  Moreover, MMPs have recently been proposed as pivotal regulators 
within the tumor stroma and regulate responses of both the cellular and noncellular 
microenvironment).196  The tumor stroma consists of several types of resident cells and 
infiltrating cells derived from bone marrow, which together play crucial roles in the 
promotion of tumor growth and metastasis.165,196  In cancer cells, TGF-β regulates MMPs 
expression.  Conversely, MMPs produced by either cancer cells or residents’ stroma 
cells, activate latent TGF-β in the extracellular matrix, and in combination facilitate the 
enhancement of tumor progression.165,192  Moreover, MMPs can promote EMT by 
proteolytic activation of TGF-β, and the same activation can be involved in the 
suppression of T-lymphocyte reaction against cancer cell proliferation.165  For a tumor 
cell to metastasize from the primary tumor requires disruption of cell-cell interactions 
from the surrounding cells.197  In addition to this, cells must also undergo detachment 
from the ECM and develop a resistance to anoikis, (apoptosis upon cell detachment from 
ECM.197  Subsequent attachment, movement and invasion of cancer cells are functionally 
facilitated by the actin cytoskeleton and tubulin as the structural component of 
microtubules.197  
TGF-β has tumor-inhibitory activity in the early stages of tumorgenesis, but it 
promotes tumor invasive characteristics in metastatic disease. Recent evidence implicates 
active (dephosphorylated) cofilin, an F-actin severing protein required for cytoskeleton 





growth suppressor to that of a promoter of prostate cancer invasion and 
metastasis.104,113,137,197-199  Consequently, cancer cells eventually lose their ability to 
adhere to adjacent neighboring cells, as well as ECM proteins.  This process leads to 
subsequent EMT, and cells acquire invasive and metastatic characteristics.137,165,200 
 
2.6  MMPs in Prostate Cancer 
 In prostate cancer tissue, there is an imbalanced expression of MMPs and TIMPs.  
This imbalance is demonstrated as a general loss of TIMPs and an upregulation of 
MMPs.  Elevated MMP activity promotes PCa progression not only by facilitating 
metastasis, but also by overwhelmingly influencing various steps of cell proliferation, 
apoptosis, angiogenesis, and EMT.201  According to numerous studies, MMPs are more 
active in the advanced stages of carcinoma.  To confirm these findings, analysis of MMP 
mRNA and protein levels in the serum and tissue samples from PCa patients has shown 
that increased expression of MMP-2, -3, -7, -9, -13, -14, -15, -and 26 are correlated with 
advanced or metastatic disease.202   The expression of these MMPs promote PCa 
progression, however with subtle differences in their patterns of expression, biological 




































Figure 11: The roles of various MMPs in the hallmarks of prostate cancer 
progression.  
 
Source: Figure adopted from Yixuan Gong, UDC-V; William, K. Oh.  Roles of Matrix Metalloproteinases 
and their Natural Inhibitors in Prostate Cancer Progression. Cancers. 2014;6, 1298-1327. 
   
 
MMP-2 belongs to the gelatinase subfamily, which is a group of proteolytic 
enzymes distinguished by their fibronectin-like gelatin-binding domain, which allows it 
ability to degrade gelatin into its sub-compounds (polypeptides, peptides, and amino 
acids).203  Moreover, increased expression of MMP-2 has been extensively reported in 
PCa,204-207 and, higher MMP-2 expression has been correlated with increased tumor 
burden, higher Gleason score, and more advanced pathological Tumor, Lymph Node, 
Metastasis (TNM) stage.208-210  To substantiate these findings, it was found that MMP-2 
expression was not present in micro metastasis and surrounding stromal cells, but rather 
present in metastatic disease, which strongly suggest that elevated MMP-2 expression 
was associated with PCa progression and metastasis.211  Although IHC staining and in 





specimens, in vitro studies of MMP-2 expression in cultured PCA cells have given 
somewhat inconsistent result.212   For instance, a study by Lokeshwar et al. conditioned 
media from freshly cultured malignant prostate explants contained a higher proportion of 
the active form of MMP-2 than normal tissues.212   
However, in another study to examine MMP-2 secretion from cultured normal 
and neoplastic prostate cells derived from different zones of the prostate, only prostate 
stromal cells secreted the pro-enzyme form of MMP-2, whereas conditioned media from 
epithelial cells of various origins demonstrated little to no pro-MMP-2 as examined by 
zymography.213  The absence of MMP-2 expression in tumor epithelial cells in the study 
can be potentially explained by the low-grade tumor samples used in the study or lack of 
stromal support in cell culture.  It was demonstrated that addition of fibronectin to cell 
culture induced high expression of pro and active forms of MMP-2 in prostate cancer cell 
lines, 214 suggesting that a cell culture model that more closely mimics the in vivo tumor 
microenvironment is critical when studying MMP expression and function in vitro.  
MMP-7 is the smallest known member of the MMP family, and is secreted as a 28 
kDa proenzyme which can be activated in vitro by APMA (4-Aminophenylmercuric 
Acetate), trypsin and high temperatures and in vivo by MMP-3 to a 19 kDa active MMP-
7 enzyme.215  Activated MMP-7 mediates the cleavage of ECM and basement membrane 
proteins such as fibronectin, collagen type IV, laminin, and others, as well as mediates 
the ectodomain shedding of pro- and anti-tumor molecules such as tumor necrosis factor-
α, Fas ligand, heparin-binding epidermal growth factor, E-cadherin and β4-integrin.216-218  





angiogenesis not only by mobilizing endogenous pro-angiogenic factors, but also by 
generating angiogenic inhibitors such as endostatin.219 
Elevated MMP-7 expression has been detected in a variety of epithelial and 
mesenchymal tumors.220,221  Likewise, in prostate cancer, 77% and 50% of prostate 
tumors were found to focally express MMP-7 by in situ hybridization analyses and 
western blotting, respectively.222  To validate these findings, a study aimed at 
investigating serum levels of various MMPs in the prostate cancer, found that circulating 
MMP-7 was significantly elevated in individuals with distant metastases, suggesting that 
MMP-7 may play a role in facilitating distant metastases.223   
A recent publication has linked MMP-7 to bone metastasis from prostatic 
adenocarcinoma.  Prostate and breast cancers are unique among solid tumors in their 
strong propensity to metastasize to bone.224,225  It has been discovered that approximately 
84% prostate cancer patients have bone metastases upon autopsy225 which further 
substantiates the need for effective MMP inhibitors.  Of the MMPs that are highly 
expressed within the tumor-bone microenvironment (MMP-2, -3, -7, -9, and -13), only 
osteoclast-derived MMP-7 significantly contributed to human breast-to-bone metastatic 
tumor growth and tumor-induced osteolysis in experimental mice, 226 suggesting that 
MMP-7 can be an effective target for advanced PCa therapies.  An additional point to 
consider in the case of MMP-7 is that studies have shown that active MMP-7 can activate 
both MMPs -2, and -9 to exacerbate cancer progression.97 
Similar to MMP-2, MMP-9 also belongs to the gelatinase subfamily.  As 





prodomain to achieve activation.  MMP-9 has been shown to be activated by other 
members of the MMP family such as MMP-2, -3,227 and  -7.97  There have been 
discrepancies in reports detailing the expression of MMP-9 in prostate cancer tissue.  
Protein expression has been reported to be either absent228,229 or present208,230 and the 
localization of MMP-9 expression reported in the literature also varies as well.  In some 
studies, MMP-9 mRNA expression  was detected only in macrophages in areas of 
prostatic inflammation 222 or along the invasive edge of higher Gleason score tumors.208  
However, according to one published study, 94.1% of prostate cancer cells actually 
expressed MMP-9 in the cytosol and intracellular MMP-9 expression was directly 
correlated with Gleason score, but not with prognosis.230  This was an interesting finding 
because it is challenging the established paradigm of MMP expression and localization.   
The discrepancies related to MMP-9 expression could be partly explained by 
differences in the degree of invasiveness of the tumor samples used in the studies or by 
the sensitivity of detection methods.  Nonetheless, it is interesting to note that in a study 
of fresh prostate tissue obtained from 22 radical prostatectomies, the overall 
collagenolytic and gelatinolytic activities was relatively low in comparison to other 
malignancies such as basal cell carcinomas, which may help explain why the majority of 
localized primary prostate tumors remain confined to the prostate for relative long 
periods of time compared to other more invasive cancers.231 
Similarly to MMP-2, MMP-9 is derived from both tumor cells and tumor 
microenvironments and plays as imperative role in the process of cancer metastasis.  





forms is thought to contribute to enhancement of prostate cancer growth, metastasis and 
angiogenesis.  LNCaP, DU-145, and PC-3 cells are commonly used prostate cancer cell 
lines that have demonstrated low, moderate, and high metastatic potential in Matrigel 
invasion assays, respectively.231,232  PC-3 cells show increased expression of MMP-9 
compared with LNCaP and DU-145, which correlate with the highest invasive activity 
among the cell lines, 232 substantiating evidence that MMP-9 is important to invasion and 
metastasis of PCa cells.  Stable expression of human MMP-9 in poorly metastatic LNCaP 
cells produced a 2 to 3-fold increase in MMP-9 activity with an associated increase in 
invasiveness, further validating the role of MMP-9 in the metastatic process.233 
MMP-9 has also been shown to be involved in the regulation of angiogenesis; 
antisense ablation of MMP-9 expression in DU-145 and PC-3 cells produced concomitant 
inhibition of the gene expression of the proangiogenic factors such as vascular 
endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1).234 
MMP-9 knockdown also increased the release of angiostatin, a key protein that 
suppresses angiogenesis and decreases secretion of VEGF, the most common and potent 
angiogenic factor, in PC-3 cells.234  Furthermore, MMP-9 can also activate urokinase 
plasminogen activator (uPA), serpin protease nexin-1 (PN-1) and other matrix proteins 
involved in the process of invasion and angiogenesis.235,236  
MMP-9 expression is regulated by tumor-stromal interactions in prostate 
cancer.237  Experimental studies which co-cultured prostate cancer and stromal cells in 
vitro demonstrated an enhanced expression of pro-MMP-9 in prostate cancer cells, and 





metastatic PC-3 cells grown in human fetal bone implants in severe combined 
immunodeficient (SCID) mice.238  An additional co-culture experiment culturing 
endothelial cells with prostate cancer cells also showed significant enhancement of 
MMP-9 expression and subsequent invasiveness of cancer cells through increased IL-6 
secretion from endothelial cells, 238 suggesting that growth factors or cytokines secreted 
by tumor cells, stromal cells, and infiltrating inflammatory cells in the tumor 
microenvironment collectively regulate MMP-9 gene expression in an autocrine and 
paracrine manner, 238 demonstrating that several cytokines and related proteins can 
regulate MMP-9 expression in prostate cancer.  Moreover, it was shown that increased 
IL-6 expression, which is often seen in advanced prostate cancer,239 resulted in activation 
of MMP-9 expression through the TGF-β pathway,238 thus indirectly implicating TGF-β 
to be an inducer and enhancer or the metastatic potential of prostate cancer cells.    
 
2.7  MMPs and TGF-β 
TGF-β and MMPs have been implicated to function in a bidirectional regulatory 
loop associated with cancer development.240  TGF-β needs to be proteolytically activated 
by MMPs in order to exert its cellular functions, but activated TGF-β in tumors 
modulates the balance of ECM remodeling by regulating the expression of MMPs and 
their tissue inhibitors TIMPs.192,240  Moreover it has been established that TGF-β 
regulates EMT, a characteristic of invasive and metastatic cells, subsequently leading to 
increased metastases in human cancer, as well as in animal cancer models.104,165  
Moreover, TGF-β is able to stimulate several MMPs in cancer cells.  According to a 





secretion of pro-MMP-2 protein, while the treatment of epithelial cells with TGF-β 
induced expression and secretion of both MMP-2 and MMP-9.  These data suggest the 
precarious role of TGF-β and its role in the regulation of MMP-2 and MMP-9 in PCa 
cells.241 
 The regulation and effects of TGF-β on MMPs can be attributed to its 
capacity to activate a plethora of signal transduction pathways and different 
transcription factors other than Smads, thus demonstrating the complexity in the 
capacity of TGF-β to regulate MMP expression in cancer cells.134,165,240  There are at 
least two different regulatory domains present in various MMPs: (1) TGF-β 
inhibitory element, TIE and (2) the Smad binding element (SBE) [43-45].  Because 
MMP-1, MMP-7, MMP-9, MMP-13, and MM-P14 contain TIE binding sites in their 
promoters, it is postulated that the expression of these MMPs may be modulated by 
TGF-β (Figure 12).142,242  
Conversely, TGF-β has also been shown to negatively regulate the transcription 
of MMP-1 and MMP-7.165,243  Molecular analyses have demonstrated that the consensus 
TIE found within the promoters of MMP-9, MMP-13, and MMP-14 were not required for 










































Figure 12. Regulatory elements within the promoter regions of human MMP genes.  
(Transcription start sites are indicated with a bent arrow and the main functionally validated cis-
elements are represented within boxes. The relative positions of the different binding sites are not 
drawn to scale.)  
 
Source: Figure adopted from Fanjul-Fernández, M. F. A.; Cabrera, S.; López-Otín, C. Matrix 
Metalloproteinases: Evolution, Gene Regulation and Functional Analysis in Mouse Models. Biochim 
Biophys Acta. 2010;1803(1), 3-19. 
 
 
Recent research has revealed that Smads can interact with members of the AP1 
family, to alter the expression of MMPs.246,247  Additionally, TGF-β can regulate MMP-
13 gene expression partially via the AP1 site and partially through interactions of Smad3 
in conjunction with JunB and Runx-2.248  Furthermore, TGF-β directly activates other 





cell signaling which culminates in the transactivation of AP1, PEA3, NF B, SP1, and 
MEF-2 transcription factors to enhance MMP promoters’ trans-activity.249-251 
TGF-β has been shown to activate numerous intracellular signaling pathways and 
this may explain its extensive role in cancer, as well as its profound impact in the 
regulation of MMPs.165  For example, TGF-β has been shown to induce the expression of 
MMP-2 by activating the TAK1-p38 MAPK in breast epithelial cells, 252,253 while 
simultaneously enhancing SW1990, (pancreatic cancer cells derived from a spleen 
metastasis), invasiveness and induction of MMP-2 expression via the activation of 
Rac1/ROS/NF B.254  Furthermore, MMP-9 has been shown to be upregulated by TGF-β 
through the activation of ERK1, 2, Rac1-ROS-NFκB, and TAK1-NFκB in transformed 
keratinocytes, breast, and hepatocellular carcinoma cells.252-254 
TGF-β also plays a major role in promoting breast cancer migration, invasion, and 
metastasis by acting at various levels: (1) on the stroma and neighboring cells 
surrounding the tumor and (2) directly on the cancer cells themselves.  Moreover, these 
pro-metastatic responses of TGF-β include the ability to remodel the surrounding ECM, 
through stimulation of matrix metalloproteinase (MMP) expression and modulation of the 
plasminogen activation system, resulting in TGFβ-mediated matrix degradation and, 








MATERIALS AND METHODS 
 
 
3.1  Chemicals and Reagents 
 
Recombinant human TGFβ1 (#100-21C) and TGFβ3 (#100-36E) were purchased 
from PeproTech (Rock Hill, NJ).  The antibody against MMP-7 (#sc-80205), MMP-7 
siRNA (#sc-41553) control siRNA (#sc-36869) and transfection reagent (#sc-99528) 
were purchased from Santa Cruz Biotechnology, Inc. (Dallas, Texas). Antibodies against 
β-Actin (#A5441) and α-Tubulin (#T5168) were purchased from Sigma-Aldrich (St. 
Louis, MO).  Anti-mouse IgG-HRP (#NA931) was obtained from GE Healthcare 
(Piscataway, NJ).   
 
3.2  Cell Culture and Cell Treatments 
Immortalized prostate luminal epithelial cell line, RWPE1, and prostate cancer 
cell lines LNCaP, DU145, and PC3 were obtained from American Type Culture 
Collection (ATCC, Rockville, MD).  E006AA cells, a prostate cancer cell line derived 
from an African American patient, were kindly provided by Dr. Shahriar Koochekpour 
(Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park 
Cancer Institute, New York, USA).256,257   RWPE1 cells were maintained in keratinocyte 
serum-free medium as previously described. 258  PC3 and DU145 cells were cultured in 





DMEM media, all supplemented with 5% FBS.258  All cells were grown and maintained 
at 37⁰C with 5% CO2.  
 To determine the effects of TGFβ1 on MMP-7, PC3 cells were cultured in 6-well 
plates at the density of 1.5 x 105 cells/well, treated with TGFβ1 (5 ng/ml) for 4, 8, and 24 
hours.  The cells were then washed with ice-cold phosphate-buffered saline (PBS) and 
lysed in lysis buffer (Cell Signaling Technology, Beverly, MA) containing 20 mM Tris–
HCl (pH 7.5), 150 mM NaCl, 1mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin and 1X 
protease inhibitor cocktail (Calbiochem, San Diego, CA). Protein concentrations were 
determined by the Lowry HS assay using the Bio-Rad DCProtein Assay kit (Bio-Rad, 
Hercules, CA) according to the instruction provided by the manufacturer.   
 
3.3  RNA Isolation, Reverse Transcription (RT), PCR and qPCR 
 Total RNA was isolated from prostate cell lines using TRIzol (Invitrogen, 
Carlsbad, CA) as previously described.259  RT-PCR reactions were performed using the 
Master Cycler PCR Systems, (Eppendorf) as previously described 260 to detect MMP-7 
mRNA levels.  Gene specific primers were designed with NCBI Primer-Blast.  The 
following primers were used: MMP-7 forward, 5’–GAGTGCCAGATGTTGCAGAA-3’; 
MMP-7 reverse, 5’–ACCCAAAGAATGGCCAAGTT-3’; L-19 forward, 5’–
GAAATCGCCAATGCCAACTC-3’; L-19 reverse, 5’–TCTTAGACCTGCGAGC 
CTCA-3’.  L19 (a ribosomal protein) was used as an internal control.  The PCR products 
were visualized on 2% agarose gels stained with ethidium bromide (Amresco, Solon, 





The real-time PCR analysis was performed using the iCycler (BioRad, Hercules, CA) in 
96 well plates. A fluorescence-based SYBR-Green Master Mix (Bio-Rad) was used in a 
volume of 25µl/well.  The following primers were used: MMP-7, forward, 5’-
TTGTATGGGGAACTGACA- 3’; MMP-7 reverse, 5’-GCCCATCAAATGGGT 
AGGAGT- 3’. GAPDH primer: forward, 5’–GAAGGTGAAGGTCGGAGTC-3’; 
reverse, 5’–GAAGATGGTGATGGGATTTC- 3’.  The thermal profile for the real-time 
PCR was as follows: (1) 95ºC for 3 min; (2) 95ºC for 10sec; (3) 56.5ºC for 30 sec;  
(4) repeating steps 2 and 3 for 40 times.  Melting curves were examined for the quality of 
PCR amplification of each sample.  Relative quantification of MMP-7 mRNA expression 
was determined using the 2-ΔΔCT method.   
 
3.4  Western Blot Analysis 
 Total cellular proteins were prepared from different prostate cell lines and were 
analyzed by Western Blot analysis as previously described.259  Cell lysates were mixed 
with Lammeli’s buffer (62.5 mM Tris, pH 6.8, 2% SDS, 5% β–mercaptoethanol, and 
10% glycerol).  Individual samples (40–50 µg protein) were subjected to SDS-PAGE in 
10% gels and transferred to PVDF membranes (Millipore) at 100V for 90 minutes.  The 
membranes were blocked with 5% fat-free milk in TBST (50 mM Tris, pH 7.5, 
containing 0.15 M NaCl, and 0.1% Tween–20) and incubated with the MMP-7 primary 
antibody at a ratio of 1:800 overnight at 4°C.  The blots were washed, and then incubated 
with anti-mouse secondary antibody conjugated with Horse Radish Peroxidase (HRP) at 
a dilution of 1:10,000 for 1 hour at room temperature.  The blots were developed in 





density of specific protein bands were acquired using the SynGene Imager (Frederick, 
MD) and analyzed by Image J Analysis Software (NIH).  Western Blots for β-actin or α-
Tubulin were probed on previously probed blots and used as loading controls. 
 
3.5  ELISA Analysis 
 
The secreted MMP-7 protein levels in culture supernatants were analyzed using a 
sandwich type MMP-7 specific ELISA kit (R & D Systems, Minneapolis, MN #DY907) 
following the manufacturer’s instructions with minor modifications.  In brief, 96-well 
plates were coated with MMP-7 capture antibody and incubated overnight at 4⁰C.  
Standards were prepared from 2ng/ml of recombinant human MMP-7 stock solution in 
concentrations ranging from 0- 2000 pg/ml using two-fold serial dilutions.  Protein 
contents of the supernatants were determined and used at a range of 75-80 μg of protein 
sample; 100 μl of standards and samples were transferred into wells of ELISA plate 
(clear microplate #DY990, R&D) for duplicate analysis.  Absorbance was read at 450 nm 
with a reference filter set to 540nm using a BioRad microplate reader.   
 
3.6  Transfection with MMP-7 siRNA  
 
To knockdown MMP-7 expression in PC3 and E006AA cells, cells were seeded 
in six-well plates at a density of 1.5 x 105 cells per well in 1.0 ml antibiotic-free MEM or 
DMEM, respectively supplemented with 5% FBS.  The cells were incubated overnight at 
37⁰C.  MMP-7 specific siRNAs or control siRNA were transfected into PC3 and 
E006AA cells using transfection reagent (Santa Cruz Biotechnology, Dallas, TX), 
following the manufacturer’s recommendation.  Transfection complexes were mixed 





medium, and allowed to incubate at room temperature in the dark for 30 minutes.  The 
transfection reagent and siRNA duplex were added to the cells.  Seventy-two hours after 
transfection, cells were trypsinized (0.25% trypsin/2.21 mM EDTA) and re-plated for 
biological assays.  Western Blot analyses were used to confirm MMP-7 protein 
knockdown.       
 
3.7  Cell Proliferation Assay 
Following transfections of PC3 and E006AA cells, cell growth assays were 
performed using manual cell counts.  In brief, PC3 cells were seeded in 24 well plates at 
a density of 2.0 x 104 cells/well, and E006AA cells were seeded in 6 well plates at a 
density of 1.0 x 105 cells/well.  Both cell lines were allowed to attach for 24 hours.  Cells 
were serum starved for 3 hours and treated with TGF-β1 (5ng/ml) and TGF-β3 (5ng/ml) 
for 72 hours, trypsinized, and counted using a hemocytometer.  Each experiment was 
performed in duplicates and was repeated at least three times using independent cell 
preparations.  Statistical analyses were performed using Student’s t test with SigmaPlot 
Analysis Software. 
 
3.8  Migration Assay 
After transfections, cell-migration assays were performed using 24-well transwell 
inserts (8 µm) as previously described with minor modifications.261,262  Chemoattractant 
solutions were prepared by diluting TGF-β1 (5 ng/ml) or EGF (10 ng/ml) into MEM 
supplemented with 0.2% BSA for PC3 cells, and DMEM supplemented with 5% FBS for 
E006AA cells.  In brief, transwell inserts were coated on both sides with 50 μg/ml Type I 





were seeded at 3 x 104 cells/insert and 2 x 104 cells/insert, respectively.  PC3 cells were 
allowed to migrate for 5 hours, whereas the E006AA cells were allowed to migrate for 24 
hours.  Migrating cells on the membrane were fixed in 3.7 % paraformaldehyde and 
stained using DAPI (Fisher Scientific Hampton, NH).  Pictures were taken in five 
different fields for average number of migrated cells to be determined.  The results are 
expressed as migration index, defined as the average number of cells per field for test 
substance/the average number of cells per field for the medium control.  Each experiment 
was performed in duplicates and was repeated at least three times using independent cell 
preparations.  Statistical analyses were performed using Student’s t test with SigmaPlot 
Analysis Software. 
 
3.9  Invasion Assay 
 
After transfection, invasive properties of PC3 and E006AA were measured using 
transwell membranes pre-coated with 50μl of 1:4 matrigel, medium dilution.  PC3 and 
E006AA cells were resuspended at a density of 5.0 × 104  cells/insert and 4.0 × 104 
cells/ml, respectively in normal growth media supplemented with 0.1 % FBS. 500 μl of 
cell suspension was added to each insert.  Cells were treated with 5ng/ml of TGF-β1 or 
TGF-β3 or 10 ng/ml EGF, and allowed to invade at 37 °C for 48 h.  Non-invading cells 
were removed using a cotton swab.  Invading cells on the membrane were fixed in 3.7 % 
paraformaldehyde and stained using the DAPI (Fisher Scientific Hampton, NH).  Pictures 
were taken, and results are expressed, precisely as described in the previous section.  





independent cell preparation.  Statistical analyses were performed using Student’s t test 
with SigmaPlot Analysis Software. 
The results are expressed as invasion index, defined as the average number of 
cells per field for test substance, the average number of cells per field for the medium 
control.  Each experiment was performed in duplicates and was repeated at least three 
times using independent cell preparation.  
 
3.10  Statistical Analysis 
Quantitative data are presented as mean ± S.E.M. and were analyzed with Student 
t test or one-way analysis of variance (ANOVA).  P values < 0.05 were considered 








4.1  MMP-7 Basal Gene Expression and Protein Levels in Prostate Cell Lines 
An analysis of the basal expression levels of MMP-7 mRNA in several prostate 
cell lines representing prostate cancer progression using RT-PCR was performed.  Figure 
13A shows MMP-7 mRNA levels constitutively expressed in all cell lines, with 
significantly higher mRNA expression in E006AA, (4.016 + 0.9 fold; p<0.05); an 
African American derived prostate cancer cell line.  Western blot analyses were also 
performed to determine the relative protein levels of MMP-7 in these prostate cell lines.  
The MMP7 protein was present in all cell lines, and the levels were slightly higher in 
RWPE1 and PC3 prostate cells compared to LNCaP, DU145, and E006AA cells (Figure 
13B).  To further examine the basal levels of secreted MMP-7 protein in normal and 
prostate cancer cell lines, conditioned media were collected from all cell lines and 
analyzed using ELISA.  The data show significantly higher secreted MMP-7 protein 
levels in E006AA cells (266.2 + 54-pg/µg protein; p<0.05) compared to RWPE1, 





















Figure 13: Basal levels of MMP-7 in prostatic cell lines: (A) total mRNAs, (B) 





















Figure 13. Continued  
 
 As shown in Figure 13A, total mRNAs were extracted and semi-quantitative 
RT-PCR analyses were performed. L-19 was used as a loading control; mRNA 
expression profiles of MMP-7 in prostate cell lines show significantly higher levels of 
MMP-7 expression in the African-American E006AA cell line than in the RWPE1, 
LNCaP, DU145, and PC3 cell lines (4μg RNA).  Figure 13B shows the Western Blot 
analysis of MMP-7 protein levels in prostate cell lines.  Total cellular proteins were 
separated by SDS polyacrylamide gel electrophoresis and blotted using an anti-MMP-
7 antibody.  Anti-β-actin was used as a loading control.  Quantitative analysis of 
relative MMP-7 protein levels present in prostatic cell lines was carried out after 






13C.  Quantitative ELISA analysis demonstrates the significantly elevated levels of 
secreted MMP-7 protein in the conditioned cell culture media.  Each bar represents 
Mean + SEM (n=3).  Significant differences between groups in a given category 
(p<0.05) are designated with different lowercase letters.   
 
4.2  The Effects of TGF-β1 on MMP-7 Expression and Secreted MMP7 Protein in 
Prostate Cancer Cells 
TGF-β has been shown to stimulate the expression of several MMPs in cancer 
cells. 263  To determine the effects of TGF-β1 on MMP-7 mRNA and protein levels in 
prostate cancer cells, total RNA, protein, and secreted MMP-7 obtained from conditioned 
culture media were collected from PC3 cells treated with or without TGF-β1 (5ng/ml) for 
24 and 48 hours.  The mRNA, protein, and secreted MMP-7 protein levels were 
determined using RT-PCR, qPCR, Western blot analysis, and ELISA, respectively.  RT-
PCR data illustrated that TGF-β1 increased MMP-7 mRNA expression 24 hours after 
treatment (Figure 14A).  Further analysis using qPCR confirmed this finding to show that 
TGF-β1 significantly increased MMP-7 mRNA 24 hours (24 hr. 1.403 + 0.035-fold; p< 
0.05) after treatment.  The data also showed a significant increase in MMP-7 mRNA 48 
hours (48hr 1.7 + 0.05-fold; p< 0.05) after treatment when compared to the 48 hour 
control (Figure 14B).  A significant increase in MMP-7 protein levels was observed 
following a 48-hour treatment with TGF-β1 (48hr 1.9 + 0.11-fold; p< 0.05) (Figure 14C).  
Another finding was that TGF-β1 can moderately increase the secreted levels of MMP-7 
protein following 24 hours of treatment (Figure 14D); however, these changes were not 

















































Figure 14. The effects of TGF-β1 on MMP-7 gene expression and protein levels: (A) 
total RNAs from treatment groups, (B) quantitative real-time PCR, (C) Western Blot 






























Figure 14. Continued 
 
 
 Figure 14A illustrates total RNAs from treatment groups were isolated and 
semi-quantitative RT-PCR was performed to determine the effects of TGF-β1 on the 
mRNA expression of MMP-7 in PC3 cells.  L-19 was used as an internal loading 
control.  Quantitative real-time PCR was performed to analyze the effects of TGF-β1 
on the expression levels of MMP-7 in PC3 cells as depicted in Figure 14B.  TGF-β1 
significantly increases the expression of MMP-7 after 24 and 48 hours of treatment.  
The relative concentration of each PCR product was determined using the 2-ΔΔCt  
method.  GAPDH was used as an internal control.  As shown in Figure 14C, a Western 
Blot analysis of MMP-7 protein levels detailing the effects of TGF-β1 after 24 and 48 
hour treatments and quantitative analysis of MMP-7 protein following TGF-β1 






Tubulin.  Figure 14D shows the Quantitative enzyme-linked immunosorbent assay 
data of secreted MMP-7 protein levels in conditioned cell culture media following 
TGF-β1 treatments.  Analysis of secreted MMP-7 levels were normalized to the total 
cellular protein concentration of seeded cells.  Data are expressed as Mean + SEM 
(n=3), and were analyzed by ANOVA and Duncan’s modified range test.  Different 
letters designate statistically significant (p <0.05) among different treatments. 
 
4.3  The Effects of MMP7 Knockdown on Cell Proliferation, Migration, and 
Invasion in PC3 and E006AA Cells 
Next, the role of MMP-7 in TGFβ-induced cell proliferation, migration, and 
invasion in prostate cancer cells was determined.  A transient knockdown of MMP-7 was 
performed using siRNA specific to MMP-7 in PC3 and E006AA cells, followed by cell 






Figure 15. Differential effects of MMP7 knockdown on TGFβ-induced cell proliferation, 











































































Figure 16. Differential effects of MMP-7 knockdown on the cell proliferation, migration, 

























Figure 16. Continued 
 
 
 Related to Figures 15A-15C, PC3 cells were transfected with siRNA to transiently 
silence the expression of MMP7 protein. Western Blots were used to confirm MMP7 
knockdown (insert). For proliferation assays, PC3 cells were seeded in 24 well plates 
following transfection (Figure 15A).  The cells were serum starved for 3 hours and then 
treated with TGF-β1 and TGF-β3 (5 ng/ml) for 48 hours followed by manual cell 
counting using hemocytometer. Following siMMP7 transfection, the migratory (Figure 
15B) and invasive behavior (Figure 15C) were measured in PC3 cells treated with 5ng/ml 
of TGF-β1 and -β3 and 10 ng/ml EGF using transwell inserts. EGF was used as a positive 
control. Each bar represents Mean + SEM (n=3). Different letters designate statistically 
significant (p <0.05) among different treatments. Cells were stained with DAPI and 






 Related to Figures 16A-16C, E006AA cells were transfected with siRNA to 
transiently silence the expression of MMP7 protein. Western Blots were used to 
confirm MMP7 knockdown (insert). Following transfection, cell proliferation assay 
were performed on E006AA cells treated with TGF-β1 and TGF-β3 (5 ng/ml) for 72 
hours followed by manual cell counting using hemocytometer (Figure 16A). 
Following siMMP7 transfection, the migratory (Figure 16B) and invasive behavior 
(Figure 16C) were measured in E006AA cells treated with 5ng/ml of TGF-β1 and -β3 
and 10 ng/ml EGF using transwell inserts. EGF was used as a positive control. Each 
bar represents Mean + SEM (n=3).  Different letters designate statistical significance 
(p <0.05) among different treatments. Cells were stained with DAPI and visualized 
under 10xobjectives.  
 The data showed that TGF-β1 did not induce cell proliferation in PC3 or 
E006AA cells.  However, the knockdown of MMP7 significantly decreased cell 
proliferation in PC3 cells (0.34 + 0.06 fold; p <0.05) (Figure 15A), but had no effect 
on cell proliferation in E006AA cells (Figure 16A).  Moreover, TGF-β1 induced cell 
migration and invasion in both cells lines, and the knockdown of MMP7 resulted in a 
significant decrease in migration in both PC3 cells (0.4 + 0.1; p <0.05) (Figure 15B) 
and E006AA cells (0.43 + 0.0034; p <0.05) (Figure 16B).  There was also a 
significant decrease in invasion in both PC3 cells (0.5 + 0.05; p <0.05) (Figure 15C) 
and E006AA cells (0.5 + 0.026; p <0.05) (Figure 16C); compared to the appropriate 
control siRNA of transfected cells.  MMP-7 knockdown also attenuated TGF-β1, 








The results presented in this study compared the relative gene expression, protein 
levels, and secreted protein levels of MMP-7 in a prostate epithelial cell line (RWPE1) 
and various established prostate cancer cell lines (LNCaP, DU145, PC3 and E006AA).  
The present study also determined the function of MMP-7 in PC3 and E006AA prostate 
cancer cells pertaining to its role in TGF-β mediated cell proliferation, migration, and 
invasion.  Our results show that all five of the prostatic cell lines express MMP-7.  
However, the relative secreted basal levels of MMP-7 are significantly higher in the 
E006AA cell line than in the epithelial cell line, RWPE1 and the prostate cancer cell 
lines: LNCaP, DU145, and PC3.   
Until now, there was no evidence of the levels of secreted MMP-7 protein from 
any of the above referenced cell lines.  These results suggest that MMP-7 gene 
overexpression is an early event in prostate cancer tumorigenesis, as in the case of 
colorectal carcinomas.264  Moreover, a recent in vivo study has corroborated these 
findings by implicating that MMP7 promotes prostate adenocarcinoma through induction 
of epithelial-to-mesenchymal transition (EMT).265  Furthermore, it has been well 
established that EMT is considered  be critical in the development of more migratory and 





increased levels of MMP7 are required for tumor formation in nude mice.268  Therefore, 
if MMP-7 is required for tumor formation, elevated levels of MMP-7 would be present in 
the earlier stages of cancer progression versus later stages of cancer.  The E006AA cell 
line was derived from an early stage of organ confined PCa; whereas the LNCaP cell line 
was derived form a supraclavicular lymph node metastasis.269  The DU-145 cells were 
derived from a brain metastasis 270 and the PC3 cell line was derived from a bone 
metastasis,271 which can all be classified as advanced or late stage carcinomas.  These 
data also suggest that MMP-7 gene expression patterns and secreted protein levels may 
participate in early events in tumor progression and that multiple members of the 
metalloproteinase family may work in concert to facilitate late-stage tumor invasion and 
metastasis. 264  MMP-7 is a secreted protein and its substrates include other MMPs.  
Moreover, MMP-7 has been shown to activate MMPs -2 and -9,272 which further 
facilitate cancer progression, and would also suggest that MMP-7 is an early regulator of 
cancer progression. 
It is well established that TGF-β can modify the expression, secretion, and 
activation of MMPs in various cancers. 192,263,273  The effects of TGF-β on the expression 
and relative protein levels of MMP-7 had not yet been determined in prostate cancer cell 
lines.  The results show that TGF-β1 can significantly induce the expression of MMP-7 
24 hours after treatment.  Moreover, TGF-β1 can moderately induce protein levels of 
secreted MMP-7 24 hours after treatment.  However, the effects on endogenous MMP-7 
protein levels cannot be seen until 48 hours following TGF-β1 treatment.  These data 





upregulating MMP-7.  This may signify the characteristic role of TGF-β1 acting as a 
tumor promoter by increasing the levels of secreted MMP-7 into the conditioned media to 
degrade components of the extracellular matrix (ECM) to facilitate cancer cell migration 
and invasion. 
Although the process of cell proliferation and migration, are essential to normal 
development and homeostasis, these processes play a detrimental role in the progression 
of prostate cancer.191  Due to the detrimental role of MMPs in cancer cell migration and 
invasion, we determined the function of MMP-7 in prostate cancer cells in hopes of 
developing alternative therapeutic strategies for controlling metastatic cancer cell 
dissemination.  MMP-7 protein was transiently knocked down in the PC3 and E006AA 
cell lines to determine its role in cell migration, invasion, and proliferation.  The data 
showed that after silencing MMP-7, cell proliferation (PC3), migration, (PC3, E006AA), 
and invasion (PC3, E006AA), were significantly reduced in control cells, TGF-β1 and 
EGF-treated cells.  These data suggest that MMP-7 may be required for TGF-β-mediated 
cell migration and invasion.  The results from this present study also support previous 
findings which demonstrate that highly malignant cells become less aggressive when 










In conclusion, we have demonstrated for the first time the relative secreted MMP-
7 protein levels from E006AA prostate cancer cells is significantly higher than the 
relative MMP-7 secreted levels of prostate epithelial cells and prostate cancer cells.  Also 
determined were the moderate effects of TGF-β signaling on the expression and relative 
protein levels of MMP-7.  Additionally, the data have shown that MMP-7 plays a 
fundamental role in the invasive and metastatic potential of cancer cells which is 
consistent with previous studies.274,275  Our findings suggest that further analysis of 
MMP-7 expression in prostate cancer may lead to more effective screening methods, and 
the development of an MMP-7 biomarker profile which can assist in the diagnosis of 
early stage organ-confined prostate cancer.  These findings can aid in the advancement of 
personalized anticancer treatment plans, help discover new molecular targets for gene 
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